Controlled-release tablets from carrageenans: effect of formulation, storage and dissolution factors

被引:64
|
作者
Gupta, VK
Hariharan, M
Wheatley, TA
Price, JC
机构
[1] Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA
[2] Pharmacia Corp, Pharmaceut & Analyt Sci, Skokie, IL USA
[3] FMC Corp, Div Pharmaceut, Princeton, NJ USA
关键词
controlled-release; sustained-release; zero-order; iota-carrageenan; lambda-carrageenan; tablets;
D O I
10.1016/S0939-6411(01)00135-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to investigate the potential of two carrageenans, tau -carrageenan and lambda -carrageenan for the preparation of controlled-release tablets. Tablets were compressed on a Carver press and the effect of formulation factors, moisture, and storage on the release of theophylline was studied. The effect of sodium chloride in the tablet formulation and a change in the ionic strength of the dissolution media was studied on the release of three model drugs. The release rate increased both with an increase in tablet diameter and increase in drug to carrageenan ratio in the tablets. The two lubricants studied had a negligible effect on the rate of drug release at their commonly used concentrations. Moisture content of carrageenans, storage of tablets at 37 degreesC/75% RH for 3 months, and incorporation of 10% sodium chloride in the tablets did not have any significant effect on the release rate. The change in ionic strength of simulated gastric fluid altered the release rate whereas the ionic strength of simulated intestinal fluid did not have a significant effect on the release rate. Carrageenan tablets were relatively insensitive to small changes in formulation parameters and dissolution conditions. (C) 2001 Elsevier Science B.V, All rights reserved.
引用
收藏
页码:241 / 248
页数:8
相关论文
共 50 条
  • [31] CONTROLLED-RELEASE COPRECIPITATES - FORMULATION CONSIDERATIONS
    KHAN, MA
    KARNACHI, AA
    SINGH, SK
    SASTRY, SV
    KISLALIOGLU, SM
    BOLTON, S
    JOURNAL OF CONTROLLED RELEASE, 1995, 37 (1-2) : 131 - 141
  • [32] Preparation and Performance of Controlled-release Tablets of Sasanquasaponin
    Liu, Xiaozhen
    Zhu, Liangwei
    Lai, Zhongfang
    Guo, Lingling
    Song, Lingling
    Shi, Yingzhen
    ADVANCED MATERIALS, PTS 1-3, 2012, 415-417 : 1713 - +
  • [33] CONTROLLED-RELEASE TABLET FORMULATION OF ISONIAZID
    JAIN, NK
    KULKARNI, K
    TALWAR, N
    PHARMAZIE, 1992, 47 (04): : 277 - 278
  • [34] A NEW CONTROLLED-RELEASE FORMULATION OF ALBUTEROL
    POWELL, ML
    WEISBERGER, M
    DOWDY, Y
    GURAL, R
    SYMCHOWICZ, S
    PATRICK, JE
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1986, 77 (01) : 152 - 152
  • [36] Blinding controlled-release tablets for clinical trials
    Felton, LA
    Wiley, CJ
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2003, 29 (01) : 9 - 18
  • [37] Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation
    Abdelkader H.
    Abdalla O.Y.
    Salem H.
    AAPS PharmSciTech, 8 (4)
  • [38] Matrix tablets based on carrageenans with dual controlled release of doxazosin mesylate
    Pavli, Matej
    Vrecer, Franc
    Baumgartner, Sasa
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 400 (1-2) : 15 - 23
  • [39] Dissolution Testing of a Controlled-Release Capsule Formulation: Challenges and Solutions Using a Semi-Automated Dissolution System
    Lo, Lili
    Lu, Xujin
    Lloyd, David
    DISSOLUTION TECHNOLOGIES, 2013, 20 (02): : 6 - 12
  • [40] Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation
    Abdelkader, Hamdy
    Abdalla, Ossama Youssef
    Salem, Hesham
    AAPS PHARMSCITECH, 2007, 8 (04):